Un nuevo informe (en inglés) de la Red de Acción Contra el Cáncer de la Sociedad Americana Contra el Cáncer (ACS CAN) descubrió que más del 70% de los pacientes con seguro comercial tuvieron gastos de bolsillo para pruebas de diagnóstico de seguimiento del cáncer de mama en 2023.
El viernes pasado, la Corte Suprema de Estados Unidos anunció su decisión de conceder la petición del gobierno para la revisión del caso (certiorari) en el caso Braidwood Management versus Becerra.
ATLANTA, Ga. – As Georgia lawmakers reconvene for the 2025 legislative session, the American Cancer Society Cancer Action Network (ACS CAN) looks forward to working with them to prioritize legislation to ease the burden of cancer on Georgians.
In proposing to increase Maine’s tax on cigarettes $1 per pack, Governor Mills’ has taken a historic step in the fight to curb tobacco product use among Mainers.
MADISON, Wis. – As Wisconsin lawmakers reconvene for the 2025 legislative session, the American Cancer Society Cancer Action Network (ACS CAN) looks forward to working with them to prioritize legislation to ease the burden of cancer on Wisconsinites.
HELENA, Montana – Residents from across the state will rally at noon on Wednesday at the Capitol Flag Plaza to send a clear and urgent message to lawmakers: It is time to remove the sunset clause from Montana Medicaid expansion.
COLUMBIA, S.C. – As the 2025 legislative session begins Tuesday, the American Cancer Society Cancer Action Network (ACS CAN) urges lawmakers to support policies that will reduce the cancer burden in the Palmetto State.
A new report by the American Cancer Society Cancer Action Network (ACS CAN) found that over 70% of commercially-insured patients encountered out-of-pocket expenses for follow-up breast cancer diagnostic tests in 2023. These follow-up tests, such as a diagnostic mammogram, MRI, ultrasound or biopsy, are medically recommended next steps to determine if an individual may or may not have cancer; however, barriers like cost can keep people from getting them.
A new report by the American Cancer Society Cancer Action Network (ACS CAN) found that over 70% of commercially-insured patients encountered out-of-pocket expenses for follow-up breast cancer diagnostic tests in 2023. These follow-up tests, such as a diagnostic mammogram, MRI, ultrasound or biopsy, are medically recommended next steps to determine if an individual may or may not have cancer; however, barriers like cost can keep people from getting them.